Three molecules show promise as epilepsy treatments in pre-clinical trials
Researchers have synthesised three oligonucleotide inhibitor molecules which stopped seizures in mouse models, making them potential epilepsy drugs.
List view / Grid view
Researchers have synthesised three oligonucleotide inhibitor molecules which stopped seizures in mouse models, making them potential epilepsy drugs.
New research has found that of the 718 pipeline drugs associated with COVID-19, 70 percent are currently in the discovery or pre-clinical stages.
The drug candidate PL8177 reduced inflammation, protected lung tissue and reduced lung fibrosis in pre-clinical models with symptoms of COVID-19.
Researchers have demonstrated that blocking CD47-mediated signalling in mice can enhance the speed of pathogen clearance, presenting a new potential form of immunotherapy.
Japanese researchers have shown that a silicon-based antioxidant agent can suppress the development of kidney failure and Parkinson's disease in rodent models.
Small molecules named CS1 (bisantrene) and CS2 (brequinar) have been developed by researchers to suppress the growth of tumours and have shown promise in mouse models.
A group of small molecules called naphthalene-based PLpro inhibitors have been shown to block the activity of a SARS-CoV-2 protein, demonstrating potential as COVID-19 therapeutics.
A compound called tartrolon E, a byproduct of bacteria from shipworms, has been identified as researchers with the potential to fight and kill several parasites, including Cryptosporidium.
Researchers have suggested that neutrophils, which contribute to the development of ARDS in COVID-19 patients, could be diverted from the lungs by rod-shaped particles in a new form of treatment.
Researchers have found that a compound named JQ1, an experimental cancer drug, extends the life of mice with Rett syndrome.
A team has successfully created a new method to artificially produce FE399, a compound known to induce apoptosis in cancer cells.
4 June 2020 | By Biosensing Instrument
In this webinar, we will provide an overview of the technology with some application examples and also see a case study how AstraZeneca is exploring SPRM for studies on G-protein-coupled receptors (GPCR) in close collaboration with Biosensing Instrument.
A group of German researchers has proposed an empty phage capsid with ligands on its surface as a novel technique to treat influenza.
Using mass spectrometry, researchers have shown how human cells are changed by infection from SARS-CoV-2, allowing the team to identify drug targets to prevent viral reproduction.
Researchers have found that molecules from ticks called Evasins have the potential to halt cytokine storms, the leading cause of COVID-19 fatalities.